Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

By CNBC | Oct 31, 2024 at 07:12 AM EST

Bristol Myers Squibb reported exceptional third-quarter earnings exceeding expectations, driven by Eliquis and growth portfolio drugs. The company raised revenue and earnings guidance for 2024 amidst cost-cutting efforts to enhance key drug brands and R&D programs.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.